4QYE

CHK1 kinase domain in complex with diarylpyrazine compound 1

4QYE の概要

• エントリーDOI: 10.2210/pdb4qye/pdb
• 関連するPDBエントリー: 4QYF 4QYG 4QYH
• 分子名称: Serine/threonine-protein kinase Chk1, 4-[6-(3-hydroxyphenyl)pyrazin-2-yl]benzoic acid (3 entities in total)
• 機能のキーワード: protein kinase, phosphotransfer catalyst, transferase-transferase inhibitor complex, transferase/transferase inhibitor
• 由来する生物種: Homo sapiens (human)
• 細胞内の位置: Nucleus: O14757
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 34497.49

構造登録者

Appleton, B.,Wu, P. (登録日: 2014-07-24, 公開日: 2014-12-17, 最終更新日: 2024-02-28)

主引用文献

Gazzard, L.,Appleton, B.,Chapman, K.,Chen, H.,Clark, K.,Drobnick, J.,Goodacre, S.,Halladay, J.,Lyssikatos, J.,Schmidt, S.,Sideris, S.,Wiesmann, C.,Williams, K.,Wu, P.,Yen, I.,Malek, S.
Discovery of the 1,7-diazacarbazole class of inhibitors of checkpoint kinase 1.
Bioorg.Med.Chem.Lett., 24:5704-5709, 2014

PubMed Abstract: Checkpoint kinase 1 (ChK1) is activated in response to DNA damage, acting to temporarily block cell cycle progression and allow for DNA repair. It is envisaged that inhibition of ChK1 will sensitize tumor cells to treatment with DNA-damaging therapies, and may enhance the therapeutic window. High throughput screening identified carboxylate-containing diarylpyrazines as a prominent hit series, but with limited biochemical potency and no cellular activity. Through a series of SAR investigations and X-ray crystallographic analysis the critical role of polar contacts with conserved waters in the kinase back pocket was established. Structure-based design, guided by in silico modeling, transformed the series to better satisfy these contacts and the novel 1,7-diazacarbazole class of inhibitors was discovered. Here we present the genesis of this novel series and the identification of GNE-783, a potent, selective and orally bioavailable inhibitor of ChK1.

PubMed: 25453805
DOI: 10.1016/j.bmcl.2014.10.063

実験手法

X-RAY DIFFRACTION (2.05 Å)